M&A Deal Summary |
|
---|---|
Date | 2022-06-22 |
Target | Alpha-5 Integrin |
Sector | Life Science |
Buyer(s) | Pasithea |
Deal Type | Add-on Acquisition |
Deal Value | 4M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2020 |
Sector | Life Science |
Employees | 8 |
Pasithea is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea was founded in 2020 and is based in Miami Beach, Florida.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Life Science) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (Virginia) | 1 of 1 |
Country (United States) | 1 of 2 |
Year (2022) | 1 of 2 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-10-12 |
AlloMek Therapeutics
Woodbridge, Connecticut, United States AlloMek Therapeutics is a biotechnology company that provides CIP-137401, a potential macrocyclic mitogen-activated protein kinase kinase 1/2 (MEK) inhibitor for use in a range of CNS-related indications, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as potential synergy with its existing multiple sclerosis (MS) development program. AlloMek Therapeutics is based in Woodbridge, Connecticut. |
Buy | - |